The Newcomer Podcast AI, Longevity, and the Health Revolution with Nayeema Raza
12 snips
Sep 19, 2025 A pivotal shift in public health is underway, driven by billionaires in pursuit of immortality and the rapid integration of AI in healthcare. The discussion highlights troubling aspects of the American healthcare system and the excitement surrounding GLP-1 drugs. Insights from a recent summit showcase how China is advancing human trials faster than the U.S. The conversation raises critical questions about the future of patient privacy and the potential misuse of AI by insurers, all while exploring the balance between technological advancement and ethical considerations.
AI Snips
Chapters
Transcript
Episode notes
GLP-1s Shift Willingness To Pay For Health
- GLP-1 drugs reshaped consumer willingness to pay for health products.
- Pharma will likely invest heavily in preventative and longevity therapies because the market now rewards out-of-pocket spending.
Dog Trials As A Longevity Launchpad
- Celine pursued dog longevity as a lower-regulatory path to human aging interventions.
- She uses pet trials as a stepping stone to human therapies and distribution control.
Wearables Crossing Into Medical Diagnosis
- Consumer wearables are moving from fitness to medical screening and FDA-cleared claims.
- This shifts responsibility: devices can flag conditions but also create new demand and anxiety.